Literature DB >> 10846104

Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.

M K Gorny1, S Zolla-Pazner.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) entry into target cells appears to be triggered when two heptad repeat regions in the ectodomain of gp41 associate, converting the prefusogenic form of gp41 to a fusogenic form. Peptides from these two heptad repeat regions, designated N51 and C43, form a coiled coil consisting of an alpha-helical trimer of heterodimers which approximates the core of the fusogenic form of gp41. To understand the antigenic structures of gp41 in these two configurations, and to examine the specificity of anti-gp41 antibodies produced by HIV-1-infected individuals, human anti-gp41 monoclonal antibodies (MAbs) were tested for their reactivity against N51, C43, and the complex formed by these peptides. Of 11 MAbs, 7 reacted with the complex but with neither of the parent peptides. These MAbs reacted optimally with the N51-C43 complex prepared at a 1:1 ratio and appeared to recognize the fusogenic form of gp41 in which the two heptad repeat regions are associated to form the coiled coil. The existence of antibodies from HIV-infected humans that exclusively recognize the N51-C43 complex constitutes the first proof that the coiled-coil conformation of gp41 exists in vivo and is immunogenic. Two of the 11 MAbs were specific for the hydrophilic loop region of gp41 and failed to react with either peptide alone or with the peptide complex, while the remaining 2 MAbs reacted with peptide C43. One of these two latter MAbs, 98-6, also reacted well with the equimolar N51-C43 complex, while reactivity with C43 by the other MAb, 2F5, was inhibited by even small amounts of N51, suggesting that the interaction of these peptides occludes or disrupts the epitope recognized by MAb 2F5. MAbs 98-6 and 2F5 are also unusual among the MAbs tested in their ability to neutralize multiple primary HIV isolates, although 2F5 displays more broad and potent activity. The data suggest that anti-gp41 neutralizing activity is associated with specificity for a region in C43 which participates in complex formation with N51.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10846104      PMCID: PMC112119          DOI: 10.1128/jvi.74.13.6186-6192.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.

Authors:  D M Eckert; V N Malashkevich; L H Hong; P A Carr; P S Kim
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

2.  Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins.

Authors:  P Chambers; C R Pringle; A J Easton
Journal:  J Gen Virol       Date:  1990-12       Impact factor: 3.891

3.  A general model for the transmembrane proteins of HIV and other retroviruses.

Authors:  W R Gallaher; J M Ball; R F Garry; M C Griffin; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1989-08       Impact factor: 2.205

4.  Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat.

Authors:  E L Delwart; G Mosialos; T Gilmore
Journal:  AIDS Res Hum Retroviruses       Date:  1990-06       Impact factor: 2.205

5.  Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe.

Authors:  J Goudsmit; R H Meloen; R Brasseur
Journal:  Intervirology       Date:  1990       Impact factor: 1.763

6.  Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

Authors:  D S Tyler; S D Stanley; S Zolla-Pazner; M K Gorny; P P Shadduck; A J Langlois; T J Matthews; D P Bolognesi; T J Palker; K J Weinhold
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

7.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

Authors:  K Javaherian; A J Langlois; G J LaRosa; A T Profy; D P Bolognesi; W C Herlihy; S D Putney; T J Matthews
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

8.  Generation of human monoclonal antibodies to human immunodeficiency virus.

Authors:  M K Gorny; V Gianakakos; S Sharpe; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

9.  Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.

Authors:  W E Robinson; T Kawamura; M K Gorny; D Lake; J Y Xu; Y Matsumoto; T Sugano; Y Masuho; W M Mitchell; E Hersh
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

10.  Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  P L Earl; R W Doms; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

View more
  48 in total

1.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

4.  Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region.

Authors:  Nathan I Nicely; S Moses Dennison; Leonard Spicer; Richard M Scearce; Garnett Kelsoe; Yoshihiro Ueda; Haiyan Chen; Hua-Xin Liao; S Munir Alam; Barton F Haynes
Journal:  Nat Struct Mol Biol       Date:  2010-11-14       Impact factor: 15.369

5.  Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.

Authors:  Antony S Dimitrov; John M Louis; Carole A Bewley; G Marius Clore; Robert Blumenthal
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

6.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Authors:  Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Marco Morelli; Yifan Cheng; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-05       Impact factor: 11.205

8.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies.

Authors:  Wen Yuan; Xing Li; Marta Kasterka; Miroslaw K Gorny; Susan Zolla-Pazner; Joseph Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.